Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD
U.K. Ophthalmologists Lead in Treatment of Wet AMD Patients with Oraya Therapy Across Europe
U.K. ophthalmologists are the leading adopters of Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), two years after the treatment was introduced in the country…Read Press Release >
Extended CE Mark brings new treatment option to patients in the United Kingdom, Germany and Switzerland…Read Press Release >
Treatment Locations NEW LOCATION IN KENT
NEW LOCATION IN KENTKent residents with wet age-related macular degeneration (AMD) now have access to the Oraya Therapy at the Kent Institute of Medicine and Surgery (KIMS) in Maidstone. The hospital has recently begun treating patients. The treatment is carried out by one of KIMS’ highly skilled team of ophthalmologists. For more information in the UK, call 0800-690-6495.
Full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.
Leading organizations and Members of Parliament come together at a special event sponsored by Oraya Therapeutics. More >
AMD Alliance International leads an event at the House of Commons addressing current issues with diagnosing, treating and managing the growing number of aging people affected by age-related macular degeneration (AMD), the leading cause of blindness in the western world.
Sir David Amess hosts a parliamentary event about age-related macular degeneration (AMD). More >
Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics. More >
Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment. More >
Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD. More >
Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye. More >
Published in Ophthalmology, January 2015.
Free Download >
Published in RETINA, February 2015. Download >
Published in Expert Reviews of Ophthalmology, 2014. Download >